dc.contributor.author |
Kitchin, Dale
|
|
dc.contributor.author |
Richardson, Simone I.
|
|
dc.contributor.author |
Van der Mescht, Mieke Adri
|
|
dc.contributor.author |
Motlou, Thopisang
|
|
dc.contributor.author |
Mzindle, Nonkululeko
|
|
dc.contributor.author |
Moyo-Gwete, Thandeka
|
|
dc.contributor.author |
Makhado, Zanele
|
|
dc.contributor.author |
Ayres, Frances
|
|
dc.contributor.author |
Manamela, Nelia P.
|
|
dc.contributor.author |
Spencer, Holly
|
|
dc.contributor.author |
Lambson, Bronwen
|
|
dc.contributor.author |
Oosthuysen, Brent
|
|
dc.contributor.author |
Kaldine, Haajira
|
|
dc.contributor.author |
Du Pisanie, Marizane
|
|
dc.contributor.author |
Mennen, Mathilda
|
|
dc.contributor.author |
Skelem, Sango
|
|
dc.contributor.author |
Williams, Noleen
|
|
dc.contributor.author |
Ntusi, Ntobeko A.B.
|
|
dc.contributor.author |
Burgers, Wendy A.
|
|
dc.contributor.author |
Gray, Glenda G.
|
|
dc.contributor.author |
Bekker, Linda-Gail
|
|
dc.contributor.author |
Boswell, Michael T.
|
|
dc.contributor.author |
Rossouw, Theresa M.
|
|
dc.contributor.author |
Ueckermann, Veronica
|
|
dc.contributor.author |
Moore, Penny L.
|
|
dc.date.accessioned |
2023-05-10T12:08:52Z |
|
dc.date.available |
2023-05-10T12:08:52Z |
|
dc.date.issued |
2022-03-15 |
|
dc.description.abstract |
The Janssen (Johnson & Johnson) Ad26.COV2.S non-replicating viral vector vaccine has been widely
deployed for COVID-19 vaccination programs in resource-limited settings. Here we confirm that neutralizing
and binding antibody responses to Ad26.COV2.S vaccination are stable for 6 months post-vaccination, when
tested against multiple SARS-CoV-2 variants. Secondly, using longitudinal samples from individuals who
experienced clinically mild breakthrough infections 4 to 5 months after vaccination, we show dramatically
boosted binding antibodies, Fc effector function, and neutralization. These high titer responses are of similar
magnitude to humoral immune responses measured in convalescent donors who had been hospitalized with
severe illness, and are cross-reactive against diverse SARS-CoV-2 variants, including the neutralizationresistant
Omicron (B.1.1.529) variant that currently dominates global infections, as well as SARS-CoV-1.
These data have implications for population immunity in areas where the Ad26.COV2.S vaccine has been
widely deployed, but where ongoing infections continue to occur at high levels. |
en_US |
dc.description.department |
Immunology |
en_US |
dc.description.department |
Internal Medicine |
en_US |
dc.description.sponsorship |
The South African Medical Research Council, the South African Research Chairs Initiative of the Department of Science and Innovation; the National Research Foundation of South Africa, the EDCTP2 program of the European Union’s Horizon 2020 program, the Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), which is supported by core funding from the Wellcome Trust and the Poliomyelitis Research Foundation, MRC UK, NRF, the Lily and Ernst Hausmann Trust and L’Oreal/Unesco Women in Science South Africa Young Talents awardee. |
en_US |
dc.description.uri |
http://www.cell.com/cell-host-microbe/home |
en_US |
dc.identifier.citation |
Kitchin, D., Richardson, S.I., Van der Mescht, M.A. et al. 2022, 'Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern', Cell Host & Microbe, vol. 3, art. 100535, pp. 1-7, doi : 10.1016/j.xcrm.2022.100535. |
en_US |
dc.identifier.issn |
1931-3128 (print) |
|
dc.identifier.issn |
1934-6069 (online) |
|
dc.identifier.other |
10.1016/j.xcrm.2022.100535 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/90615 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
Cell Press |
en_US |
dc.rights |
© 2022 The Author(s).
This is an open access article under the CC BY-NC-ND license. |
en_US |
dc.subject |
Omicron (B.1.1.529) variant |
en_US |
dc.subject |
Ad26.COV2.S |
en_US |
dc.subject |
Vaccine |
en_US |
dc.subject |
Infections |
en_US |
dc.subject |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
en_US |
dc.title |
Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern |
en_US |
dc.type |
Article |
en_US |